Lymphoma News

The FDA has requested manufacturers of commercially available chimeric antigen receptor T-cell therapies now include a boxed safety warning regarding the risk for secondary T-cell malignancies on prescribing labels.

SAN DIEGO — Limited duration loncastuximab tesirine in addition to rituximab appeared well tolerated and highly effective for relapsed or refractory follicular lymphoma, according to data presented at ASH Annual Meeting and Exposition.

In this video, Stephen M. Ansell, MD, PhD, discusses primary analysis results from the phase 3 Sympatico study.

SAN DIEGO — The volume of hematopoietic stem cell transplantation procedures for advanced diffuse large B-cell lymphoma has declined precipitously since 2019, study results presented at ASH Annual Meeting and Exhibition showed.

Benefits of chimeric antigen receptor T-cell therapy far outweigh the risks involved, including secondary T-cell malignancies, according to Peter Marks, MD, PhD, director of the FDA’s Center for Biologic Evaluation and Research.

Researchers found lisocabtagene maraleucel to be a cost-effective second-line treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma, study findings published in Blood Advances showed.

Curative potential at a longer follow-up, logistics and patient risk and eligibility are all important considerations when sequencing bispecific antibodies and chimeric antigen receptor T-cell therapy for advanced large B-cell lymphoma.

In this video, Stephen M. Ansell, MD, PhD, discussed updated study results showing an advantage of nivolumab-chemo over brentuximab vedotin-chemo in both younger and older patients.

This year’s ASH Annual Meeting featured several high-impact abstracts.

In this video, Brian T. Hill, MD, PhD, discusses research that evaluated the effectiveness of chemo-immunotherapy against three novel combination therapies in the second line or later for patients with relapsed/refractory large B-cell lymphoma.